In recent years, brain-computer interface (BCI) technology has emerged as a new frontier in U.S.-China tech competition. The U.S. got an early start, with companies like Neuralink already conducting animal trials and even early human implants, backed by deep technical expertise. China, supported by national policies and massive R&D investment, is rapidly catching up—leading institutions such as Tsinghua University, Fudan University, and companies like BrainCo have made significant advances in non-invasive and semi-invasive BCI systems. Technologically, the U.S. favors high-bandwidth, high-precision invasive approaches aimed at long-term human-machine integration, while China prioritizes safety and clinical applications, focusing on medical rehabilitation. Both nations hold distinct advantages: the U.S. benefits from a world-class research ecosystem and venture capital, whereas China leverages vast data resources, rapid engineering deployment, and strong policy execution. In the short term, the U.S. maintains a lead, but China is narrowing the gap through an ‘application-driven + national strategy’ model. Ultimately, victory will depend not just on breakthrough innovations, but on the broader capacity to build ecosystems, establish ethical frameworks, and translate research into real-world impact.
近年来，脑机接口（BCI）技术成为中美科技竞争的新焦点。美国在该领域起步较早，Neuralink等企业已实现动物实验甚至早期人体植入，技术积累深厚；而中国则依托国家政策支持和庞大科研投入，在高校与企业协同下快速追赶，如清华大学、复旦大学及脑虎科技等机构已取得非侵入式与半侵入式BCI的重要突破。从技术路线看，美国偏重高带宽、高精度的侵入式方案，追求长期人机融合；中国则更注重安全性和临床转化，优先发展医疗康复等应用场景。在人才储备、芯片制造、算法优化等方面，两国各有优势：美国拥有全球顶尖科研生态与风险资本支持，中国则具备数据规模、工程落地速度与政策执行力。总体而言，短期内美国仍处领先地位，但中国正以‘应用驱动+国家战略’模式加速缩小差距。未来胜负不仅取决于单一技术突破，更在于生态构建、伦理规范与产业转化能力的综合较量。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/10029.html